



ELSEVIER

Contraception

Contraception 74 (2006) 499–502

Author Index
Volume 74
July–December, 2006

- Abraham, B., 188
Abuabara, K., 394
Ahrendt, H.-J., 451
Ajayi, A., 194
Akin, A., 376
Akkuzu, G., 376
Aldrighi, J.M., 446
Ali, N., 125
Alibayeva, G., 318
Alizade, S.M., 483
Allen, R.H., 407
Ambardekar, S., 179
Anderson, F., 181
Anderson, F.D., 355
Andrade, R.P., 446
Andrist, L.C., 174
Archer, D., 179
Archer, D.F., 359, 439
Arias, R.D., 234
Arkutu, A., 194
Aronsson, A., 31
Arslin, A., 191
Ashraf, A., 382
Auerswald, C., 186

Badon, S., 194
Baga, R.I., 483
Bahamondes, L., 259
Baird, D., 3
Bajos, N., 195, 208, 476
Ballagh, S., 179
Ballagh, S.A., 133
Bankole, A., 188
Bapst, J.L., 414
Barbosa, I.C., 492
Barnes-Harper, K.T., 214
Barmhart, K., 182, 192
Bastianelli, C., 451
Bautista, C.T., 318
Bay, R.C., 313
Becker, B.M., 201

Bednarek, P., 178
Belfield, T., 280
Benedict, C., 180
Betstadt, S., 193
Bitzer, J., 451
Black, K.I., 309
Blanchard, K., 176
Blum, J., 191, 194
Blumenthal, P., 191
Blumenthal, P.D., 249, 272
Bock, B.C., 201
Borenstein, J., 249
Borges, L.E., 446
Borisute, H., 439
Borrero, S., 193
Bost, J., 193
Botto, A., 492
Bouyer, J., 118, 188
Brache, V., 133
Bracken, H., 179
Brenner, P., 354
Broyles, M., 189
Brucker, C., 234
Burke, A., 183
Burrows, M., 487
Bygdeman, M., 31

Cagiano, R., 220
Cahill, S., 36
Callahan, M., 133
Camargos, A.F., 446
Camus, A., 197
Candel, A., 328
Carbonell Esteve, J.L., 328
Carerra, J., 188
Carlson, N., 196
Carr, J.K., 318
Castleman, L., 36
Castleman, L.D., 272
Chavira, W., 313
Chen, P., 181

Cheng, L., 61
Chung-Park, M., 196
Clark, L.R., 214
Clark, M.A., 201
Clark, S., 195
Cohen-Landau, S., 194
Cohn, L., 195
Colwell, H.H., 303
Constantine, G.D., 439
Coonrod, D.V., 313
Cooper, E., 183
Copas, A.J., 224, 498
Costales, A., 178, 184
Coulhart, S., 157
Coutinho, E., 492
Coyaji, K., 179
Creinin, M., 133, 178, 179, 181, 182,
184, 186, 193, 458
Cremer, M., 176, 191
Crockett, S.A., 174
Croxatto, H., 181
Cushman, L., 180, 192
Cwiak, C., 186, 191

Dalton, V., 195
Damergis, J.A., 201
Danielsson, K.-G., 66
Daponte, A., 324
Darney, P., 104
Dauphinee, L.A., 334
Davey, A., 16
Davis, A., 197
Davis, S., 179, 187
Dela Cruz, M., 180
Deloughery, T., 191
Deutsch, M., 345
Dhanaraju, M.D., 148
Diaz Olavarrieta, C., 193
Diaz-Olavarrieta, C., 264
Diaz-Olavarrieta, C., 394
Dilbaz, B., 376

- Dimopoulos, K.D., 324
 Diop, A., 191, 194
 Doh, A.S., 118
 dos Santos Fernandes, A.M., 259
 Downing, D., 185
 Doyle, L.L., 351
 Dries-Daffner, I., 190
 Dubois, R.W., 249
- Earhart, K.C., 318
 Edelman, A., 191
 Edelman, A., 196
 Edwards, S., 180, 192
 Egger, K., 367
 El-Mallah, S.Y., 297
 Epstein, L., 186
 Equils, O., 175
 Erben, R.G., 367
 Eren, B., 224
 Erens, B., 498
 Ermer, J.C., 414
 Eroğlu, K., 376
 Espey, E., 184, 389
- Falk, G., 471
 Fang, A., 187
 Fatuma, A.B., 400
 Felsenberg, D., 367
 Fendrick, A., 195
 Fenton, K., 224, 498
 Ferron, G.M., 414
 Fiala, C., 66
 Fichorova, R.N., 133
 Finer, L., 186
 Finer, L.B., 334
 Fitzmaurice, G., 407
 Fogg, K., 191
 Fogle, R.H., 245
 Fortner, K., 190
 Foss, D., 414
 Fosse, I., 190
 Foster, A., 193
 Foster, A.M., 264
 Foster-Rosales, A., 180
 Frederick, C., 196
 Frezieres, R.G., 110
 Friedman, A.J., 303
 Frimpong, P., 194
 Frohwirth, L.F., 334
- Gainer, E., 118
 Gallo, M.F., 36
 Galper, C., 189
 Gardner, J., 185
 Gaydos, L., 188
- Gazi, R., 382
 Gee, E.M., 201
 Gemzell-Danielsson, K., 31, 451
 Gerdts, C., 190
 Ghosh, D., 419
 Gilbert, F., 208
 Gill, G., 184
 Gilliam, M., 179, 187
 Ginsburg, K.R., 214
 Glasier, A.F., 287
 Glik, A., 345
 Gmach, R., 382
 Godfrey, E., 189
 Göhler, K., 239
 Gold, M., 185, 189
 Goldberg, A.B., 407
 Goldfarb, I., 194
 Gómez, M.A., 451
 Goodman, S., 180
 Goulard, H., 208
 Granot, M., 345
 Grimes, D.A., 174, 280
 Grossman, D., 394
 Grubb, G.S., 439
 Guazelli, C., 446
 Guidozzi, F., 324
 Guo, A., 249
 Gupta, R.C., 165
 Guzick, D., 183
- Haberal, A., 376
 Halmesmäki, K., 182
 Harper, C.C., 104
 Harris, L., 195
 Hart, K.W., 313
 Hartard, M., 367
 Harwood, B., 179, 181, 182, 184, 190
 Harwood, B.J., 458
 Hassan, M., 297
 Hayes, J., 181
 Hazarika, A., 426
 Hearst, N., 196
 Heartwell, S., 180, 192
 Helmerhorst, F.M., 280
 Hicks, S., 191
 Hillier, S., 182
 Hillier, S.L., 133
 Ho, P.C., 11, 26
 Hockert, P., 194
 Hogue, C., 188
 Holmes, W.C., 214
 Holmquist, S., 187
 Hubacher, D., 181
 Hurskainen, R., 182
 Hwang, A.C., 435
- Hyman, A.G., 272
 Ibrahim, S., 193
 Isaia, C.F., 446
 Ivey, S., 186
- Jain, J.K., 234, 293
 Jakobi, P., 345
 James, E., 185
 Jamshidi, R., 183
 Janowitz, B., 382
 Jayakumar, R., 148
 Jenabi, E., 483
 Jensen, J., 178, 184, 186, 196
 Jensen, J.T., 439
 Jick, H., 290, 354
 Jick, S.S., 290, 354
 Job-Spira, N., 208
 Joffe, C., 1
 Johnson, A., 183
 Johnson, A.M., 224, 309, 498
 Johnson, J.V., 439
 Jones, R., 188
 Jordan, B., 87, 199
 Juliato, C.T., 259
- Kalmuss, D., 180, 192
 Karasek, D., 195
 Karskov, B., 451
 Karvois, D.L., 303
 Katz, A.I., 176
 Kaunitz, A.M., 90
 Kaye, J.A., 354
 Kayembe, P.K., 400
 Kenfack, B., 118
 Kim, L., 104
 Kleinmond, C., 367
 Kneip, C., 239
 Korner, P., 178, 184
 Kost, K., 188
 Kottke, M., 191
 Kramer, M., 188
 Krishna, U., 179
 Kritzer, J., 197
 Krohn, M., 179
 Kuehl, T.J., 100
 Kulier, R., 280
 Kumar, A., 194
 Kumar, D., 407
 Kumar, V., 165
 Kunins, H., 185
- Lai, J.-J., 133
 Lakha, F., 287
 Lal, J., 165

- Lalitkumar, P.G., 419
 Lalor, M., 186
 Landau, S., 190
 Landau, S.C., 463
 Lara, D., 394
 Lawton, B., 353
 Le, S., 185
 Leal, P., 328
 Lee, C., 389
 Leeman, L., 184, 389
 Leggat, M., 179
 Leng, X., 141
 Leonard, C.J., 313
 Lifford, K.L., 407
 Lillo, S., 181
 Lindberg, L., 186
 Lintu, H., 178
 Liu, C.Y., 104
 Liu, Z., 249
 Llorente, M., 328
 LoCoco, J.M., 303
 Lohr, P., 181, 182
 Lopes, A.C., 492
 Lopes, R., 492
 Lowenstein, L., 345
 Lui, Y.-X., 157
 Luppa, P., 367
- Ma, G., 141
 MacDonald, J., 352
 Macdowall, W., 224, 498
 Mactyszczyk, S., 157
 Magnuson, A., 471
 Mahnert, N., 192
 Maia, H. Jr., 492
 Maitra, N., 280
 Mambu, T., 400
 Mandelkar, A., 179
 Mapatano, M.A., 400
 Mari, J.M., 328
 Marions, L., 21
 Marques, M., 190
 Martin, S., 193
 Masch, R., 191
 Mathias, S.D., 303
 Mauck, C., 133
 Mboudou, E., 118
 McClung, M.R., 90
 McGhee, B.T., 463
 McGregor, J.A., 175
 McNeil, M., 193
 Meckstroth, K., 194
 Méndez, J.F., 382
 Mercer, C., 224, 498
 Mercer, C.H., 309
- Merchant, R.C., 201
 Meyn, L., 178, 179
 Michaelson, J., 189
 Milan, F., 185
 Miller, L., 185
 Miller, P.D., 90
 Miller, S., 196
 Milsom, I., 451
 Mitchell, E.M., 36
 Mittal, S., 56
 Mohsen, I.A., 297
 Monastersky, N., 194
 Moore, A.M., 334
 Moreau, C., 188, 195, 208, 476
 Mullen, P.D., 350
 Muñoz, E., 328
 Murphy, P.A., 245
 Myers, E.R., 277
- Najwa, A.R., 419
 Nanchahal, K., 224, 498
 Nasso, J., 183
 Nelson, A., 178, 184, 194
 Nguer, R., 382
 Nguyen, D., 190
 Nguyen, T., 184
 Nilsson, K., 471
 Nisand, I., 451
 Noronha, C., 492
 Nzewenga, G., 324
- Oanh, K.T.H., 272
 O'Brien, P., 280
 Oeyen, L., 451
 Ogburn, T., 184, 389
 Okonofua, F., 194
 Olenja, J., 382
 Olubuyide, T., 185
 on behalf of the participants of the
 consensus meeting held at the
 Bellagio Study and Conference
 Center, 3
 O'Neill, E., 186
 Orczyk, G.P., 414
 Östlund, I., 471
 Öznel, B., 293
- Paavonen, J., 182
 Pack, A., 197
 Page, G., 451
 Patel, A., 183, 187
 Patel, D., 183, 187
 Peixoto, F.C., 446
 Penney, G., 45
 Pera-Floyd, M., 180
- Perez, M., 194
 Peters, C., 487
 Petracco, A., 446
 Pillai, S., 187
 Piotrowskin, H., 183, 187
 Poindexter, A.N., 125
 Posner, S., 125
 Preskill, F., 195
 Prezioso, A., 351
 Pritchard, M.L., 303
 Pruitt, S.L., 350
- Qualls, C., 389
- Raine, T., 186
 Raine, T.R., 104
 RajKannan, R., 148
 Rakotovao, J., 191
 Raote, V., 179
 Ray, A., 234
 Raymond, E., 179, 349
 Reddy, S., 389
 Reeves, M., 180, 181, 182, 184
 Reeves, M.F., 458
 Reyes, V., 181
 Rice, V.M., 90
 Robertson, P., 195
 Rose, S., 353
 Rosenberg, K., 196
 Ross, D., 90, 234
 Rouhana, A., 264
 Rubin, S., 189
 Russmann, S., 354
- Sabatini, R., 220
 Salvador, I., 328
 Sambol, N.C., 104
 Sammel, M., 182
 Sampson, O., 196
 Sanchez, J.L., 318
 Sangi-Haghpeykar, H., 125
 Sankey, H., 193
 Santelli, J., 186
 Sarma, H.N., 426
 Saxena, S., 224, 498
 Schaff, E., 42
 Schaffter, K., 193, 264
 Schollin, J., 471
 Schreiber, C., 178, 182, 184, 458
 Schwartz, J.L., 133
 Schwarz, D.F., 214
 Schwarz, E., 193
 Selvaraj, D., 148
 Sengupta, J., 419

- Seoudi, S., 297
Serrano, M., 328
Shaarawy, M., 297
Shand, C., 352
Shepherd, J., 353
Shields, W.C., 1, 199, 351, 435
Shittu, O., 194
Shotorbani, S., 185
Siler-Khodr, T.M., 157
Simões, J.A., 259
Singh, M.M., 165
Singh, R., 183
Singh, R.H., 249
Singh, S., 186, 188, 334
Sitruk-Ware, R., 48, 352
Smith, T., 186
Sobota, M., 185
Sobreira-Lima, B., 259
Sokal-Gutierrez, K., 186
Song, C., 141
Sparrow, M., 352
Spiekerman, A.M., 100
Stanczyk, F.Z., 245, 293
Stanwood, N., 183
Steinauer, J., 195
Stewart, F.H., 435
Stuart, G., 192
Sulak, P.J., 100
Sun, H., 141

Tamir, A., 345
Tang, O.S., 26

Tao, S.-X., 157
Tapias, M.P., 463
Taşkin, L., 376
Taylor, J., 194
Taylor-McGhee, B., 190, 194
Teperi, J., 182
Terlinden, R., 239
the Cocon Group, 208
Thuy, L.T., 272
Todd, C.S., 318
Treece, Y., 181
Trouton, K., 187
Trussell, J., 87, 188, 193, 195, 249,
 264, 476
Tudela, A., 328

Uddin, M., 178, 184
Uragg, H., 239
Urdl, W., 451

Valero, F., 328
Vamsadhara, C., 148
Varela, L., 328
Vaughan, B., 188
Venkat, P., 191
Villarreal, M., 259
von Herten, H., 3
Vulis, M., 194
Vural, G., 376

Wagner, M., 178
Waheed, K., 189

Wallace, L., 180, 190
Walsh, T.L., 110
Ward, D., 357
Warkol, R., 185
Weber, A., 183, 187
Wei, P., 157
Weiner, D.H., 133
Weissenbacher, E.R., 367
Wellings, K., 224, 309, 498
Wesson, J., 382
Westhoff, C., 180, 181, 192
Westhoff, C.L., 245
White, T., 293
Wiebe, E., 187
Willis, S.A., 100
Winikoff, B., 176, 179,
 191, 194
Wiseman, M., 367
Wynn, L., 193, 264

Yang, J., 141
Yazlle, M.E.H., 446
Yoon, A., 197
Young, V., 190
Yount, K., 188
Yu, F.-Q., 157

Zelger, O., 367
Zepeda, A., 181
Zieman, M., 180, 192
Zimmer, E.Z., 345
Zite, N., 179-181, 185, 190

Subject Index
Volume 74
July–December, 2006

- Abortifacients, pharmacy access in a Latin American city, 394
- Abortion,
in the United States, timing of steps and reasons for delays in obtaining of, 334
utilization, relation to HIV infection among female sex workers in Tashkent, Uzbekistan, 318
- Abstracts, ARHP 2006 meeting, 178
- Acceptability,
CS gel, 133
IUD checklist screening tool, provider views on, 382
medical abortion, review, 11
mifepristone and multiple misoprostol doses for abortion up to 10 weeks of gestation, review, 36
oral vs vaginal misoprostol regimens for medical abortion, 176
- Adolescents,
vs adults, pharmacokinetics of single-dose LNG, 104
women, perceptions on menstrual irregularity caused by hormonal contraception, 214
- Adults, vs adolescents, pharmacokinetics of single-dose LNG, 104
- Advance provision, vs information, impact on EC use by age and ethnicity, randomized trial, 110
- Age, EC use based on, impact of advance provision vs information, randomized trial, 110
- Amlodipine, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Amoxicillin, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Analgesia,
requirements, and pain, during medical abortion, review, 45
suppository, efficacy in postabortion pain reduction, 345
- Androgenicity, of progestin in OC pills, effects on maximal leg strength, 487
- Anesthesia, local, with or without lorazepam or intravenous sedation for pain in first-trimester surgical abortion, 407
- Anti-leukemia inhibitory factor monoclonal antibody, effects on blastocyst implantation (rhesus monkey), 419
- Antiandrogenic activity, of OC pills, effects of St. John's Wort on, 245
- ARHP (Association of Reproductive Health Professionals)
- Association of Reproductive Health Professionals (ARHP) editorial,
adding value to reproductive health research, 199
maximizing benefit of HPV vaccines, 277
mechanism of action of EC pills, 87
morality and the abortion provider, 1
reasons for reading editorials, 357
ten priorities for women's health, 435
- Association of Reproductive Health Professionals (ARHP) 2006 meeting, abstracts, 178
- Atenolol, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Attitudes,
on contraception, between Hispanic and non-Hispanic whites, 125
of women
and providers toward menstrual suppression with extended use OC, 174
toward pharmacy access to hormonal contraception, 463
urban Hispanic, on natural family planning, 313
- Biocompatibility, of injectable PLG microspheres containing LNG + EE, 148
- Biodegradable contraceptive implant, long-acting LNG-releasing, preclinical studies (rats and dogs), 141
- Biodegradation, of injectable PLG microspheres containing LNG + EE, 148
- Blastocyst implantation, effects of anti-leukemia inhibitory factor monoclonal antibody (rhesus monkey), 419
- Bleeding pattern,
after LNG EC, 118
in subcutaneous injection of DMPA, 234
after use of LNG EC pills, 349

- BMD (Bone mineral density)
 Bone geometry, effects of desogestrel vs LNG, 367
 Bone mass, effects of desogestrel vs LNG, 367
 Bone mineral density (BMD),
 effects of desogestrel vs LNG, 367
 effects of long-term DMPA use, 297
 in users of two kinds of once-a-month combined
 injectable contraceptives, 259
 in women aged 25–35 years, effect of DMPA, 90
 Bone remodeling, effects of long-term DMPA use, 297
 Breastfeeding women, in New Mexico, conformity of OC
 prescribing with current guidelines, 389
 Buccal administration, misoprostol, and manual vacuum
 aspiration, for second-trimester abortion in Vietnam,
 272
- C-reactive protein, effects of OC vs transdermal patch,
 293
- Cefixime, effects on postcoital contraceptive efficacy
 and pharmacokinetic profile of centchroman (rats),
 165
- Cellulose sulfate (CS) gel, safety and acceptability, 133
- Centchroman, effects of coadministered drugs on postcoital
 contraceptive efficacy and pharmacokinetic profile
 of (rats), 165
- Cerebral venous sinus thrombosis, in users of four hormonal
 contraceptives, 290
- Cervical priming, in first-trimester abortion, vaginal vs
 sublingual misoprostol for, 328
- Cesarean section (CS), previous single, vaginal misoprostol
 for TOP in women with, 324
- China, medical abortion in early pregnancy, review, 61
- Chlormadinone acetate (CMA), pharmacokinetics
 after single and multiple oral doses of CMA + EE,
 239
- Ciprofloxacin, effects on postcoital contraceptive efficacy
 and pharmacokinetic profile of centchroman (rats),
 165
- Clostridium sordellii*, causing mifepristone-induced septic
 shock, 174
- CMA (Chlormadinone acetate)
- COC (Combine oral contraceptive)
- Cochrane Fertility Regulation Group, best evidence on
 family planning, 280
- Combined oral contraceptive (COC), vs vaginal ring, cycle
 control, tolerability and sexual satisfaction among
 users, 220
- Complications, of IUD insertion in immediate postplacental/
 early postpartum period, 376
- Continuation rate,
 Implanon® in the UK, 287
 TCu380A IUD in Tabriz, Iran, 483
- Contraception,
 international perspective, 351
 after medical abortion, review, 56
- Contraceptive activity, of GnRH II analog (rhesus
 monkeys), 157
- Contraceptive efficacy, postcoital, of Centchroman, effects
 of coadministered drugs on (rats), 165
- Contraceptive failure, and determinants of EC use, 208
- Contraceptive implants,
 biodegradable long-acting LNG-releasing, preclinical
 studies (rats and dogs), 141
- Uniplant, effects on endometrial morphology and ovarian
 function, 492
- Contraceptive patch, vs OC, cerebral venous sinus
 thrombosis in users of, 290
- Contraceptive technology, improvement of, 350
- Contraceptive use,
 among Hispanic vs non-Hispanic whites, 125
 EC, and contraceptive failures, 208
- EC pills, determinants and circumstances of, in the context
 of direct pharmacy access in France, 476
- and knowledge, among female ED patients, 201
- modern, in Kinshasa, Democratic Republic of Congo,
 prevalence and determinants, 400
- relation to HIV infection among female sex workers in
 Tashkent, Uzbekistan, 318
- and sexual behavior, among women, ethnic variations in,
 224
- Corticosteroid-binding globulin, effects of OC vs
 transdermal patch, 293
- Cost-effectiveness, of OC vs LNG-releasing IUS vs surgery
 for DUB, 249
- CS (Cellulose sulfate)
- Death, risk in mifepristone medical abortion, 174
- Democratic Republic of Congo, prevalence and determinants
 of modern contraceptive use in Kinshasa, 400
- Depot medroxyprogesterone acetate (DMPA),
 bleeding patterns in subcutaneous injection of, 234
 effect on BMD in women aged 25–35 years, 90
 long-term use, effects on BMD and bone remodeling, 297
- Desogestrel,
 vs LNG, skeletal effects, 367
 OC, vs contraceptive patch, cerebral venous sinus
 thrombosis in users of, 290
- Dilation and evacuation, using manual vacuum aspiration
 and buccal misoprostol for second-trimester abortion
 in Vietnam, 272
- Discontinuation, reasons for, of TCu380A IUD in Tabriz,
 Iran, 483
- DMPA (Depot medroxyprogesterone acetate)
- Drospirenone + EE,
 efficacy and safety in women with premenstrual
 disorders, 446
- oral, vs NuvaRing, efficacy, safety and tolerability, 451
- DUB (Dysfunctional uterine bleeding)
- Dysfunctional uterine bleeding (DUB), cost-effectiveness
 of surgery vs LNG-releasing IUS vs OC, 249

- EC (Emergency contraception)
 ED (Emergency department)
 EE (Ethinyl estradiol)
 Efficacy,
 continuous LNG + EE, 439
 drospirenone + EE in women with premenstrual disorders, 446
 IUD insertion in immediate postplacental/early postpartum period, 376
 mifepristone + misoprostol for medical abortion, review, 21
 mifepristone and multiple misoprostol doses for abortion up to 10 weeks of gestation, review, 36
 NuvaRing vs oral EE + drospirenone, 451
 oral vs vaginal misoprostol regimens for medical abortion, 176
 Seasonique™, 355
 suppository analgesia for postabortion pain reduction, 345
 Emergency contraception (EC),
 advance provision vs information, impact on use by age and ethnicity, randomized trial, 110
 hormonal, sociodemographic and sexual health profile of users, 309
 LNG, bleeding pattern after, 118
 use of, and contraceptive failures, 208
 Emergency contraception (EC) pills,
 bleeding patterns after use of LNG, 349
 determinants and circumstances of contraceptive use in the context of direct pharmacy access in France, 476
 mechanism of action, ARHP editorial, 87
 Emergency department (ED), contraceptive use and knowledge among female patients, 201
 Endometrial hyperplasia, effects of *Polygonum hydropiper* root extract (rats), 426
 Endometrial morphology, effects of Uniplant, 492
 Estradiol, reduced ovarian production due to shortened hormone-free interval of OC regimens, 100
 Estrogen-sensitive hepatic proteins, effects of OC vs transdermal patch, 293
 Ethynodiol dihydrogesterone (EDG),
 continuous low-dose, safety and efficacy of extended-regimen OC utilizing, 355
 pharmacokinetics after single and multiple oral doses of CMA + EDG, 239
 Ethynodiol dihydrogesterone (EDG) + drospirenone,
 efficacy and safety in women with premenstrual disorders, 446
 oral, vs NuvaRing, efficacy, safety and tolerability, 451
 Ethynodiol dihydrogesterone (EDG) + LNG,
 in injectable PLG microspheres, biodegradation and biocompatibility of, 148
 safety and efficacy of continuous regimen, 439
 Ethynodiol dihydrogesterone (EDG) + norgestimate, OC vs transdermal patch, risk of nonfatal VTE in women using, 354
 Ethnic groups, variations in sexual behavior and contraceptive use among women, 224
 Ethnicity, EC use based on, impact of advance provision vs information, randomized trial, 110
 Extended cycle OC, utilizing continuous low-dose EE, safety and efficacy, 355
 Family planning,
 best evidence on, Cochrane Fertility Regulation Group, 280
 natural, attitudes among urban Hispanic women, survey of, 313
 Females. *see* Women
 Follicular recruitment, effects of *Polygonum hydropiper* root extract (rats), 426
 France, determinants and circumstances of EC pill use in the context of direct pharmacy access, 476
 Gemeprost, shortened time interval after mifepristone for medical abortion, review, 42
 Glibenclamide, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
 GnRH II analog (Gonadotropin-releasing hormone (GNRH) II analog)
 Gonadotropin-releasing hormone (GnRH) II analog, contraceptive activity of (rhesus monkeys), 157
 Gonadotropins, reduced pituitary secretion due to shortened hormone-free interval of OC regimens, 100
 Healthy education, usage patterns of a multilingual web site on TOP information, 264
 Hepatic proteins, estrogen-sensitive, effects of OC vs transdermal patch, 293
 Hispanics,
 vs non-Hispanic whites, contraceptive knowledge, attitude and use, 125
 urban women, survey of attitudes on natural family planning, 313
 HIV infection (Human immunodeficiency virus (HIV) infection)
 Hormonal contraception,
 4 types, cerebral venous sinus thrombosis in users of, 290
 adolescent women's perceptions on menstrual irregularity caused by, 214
 emergency, sociodemographic and sexual health profile of users, 309
 long-term use of DMPA, effects on BMD and bone remodeling, 297
 survey on women's attitudes toward and interest in pharmacy access to, 463
 Hormone-free interval of OC use, shortened, causes greater inhibition of the pituitary-ovarian axis, 100
 HPV vaccines, maximizing benefit of, ARHP editorial, 277

- Human immunodeficiency virus (HIV) infection, relation to contraception and abortion utilization among female sex workers in Tashkent, Uzbekistan, 318
- Hyperplasia, endometrial, effects of *Polygonum hydropiper* root extract (rats), 426
- Implanon®, continuation rate in the UK, 287
- Induced abortion, using mifepristone, atypical presentation of PID after, 352
- Inhibin-B, reduced ovarian production due to shortened hormone-free interval of OC regimens, 100
- Injectable contraceptive, once-a-month combined, BMD in users of, 259
- PLG microspheres containing LNG + EE, biodegradation and biocompatibility of, 148
- Interest, of women in pharmacy access to hormonal contraception, 463
- Internet, usage patterns of a multilingual web site on TOP information, 264
- Intrauterine device (IUD), checklist screening tool, provider views on acceptability of, 382
- efficacy and complications of insertion in immediate postplacental/early postpartum period, 376
- TCu380A, continuation rates and reasons for discontinuation in Tabriz, Iran, 483
- Intrauterine system (IUS), LNG-releasing, vs OC, vs surgery, for DUB, cost-effectiveness of, 249
- Iran, continuation rates and reasons for discontinuation of TCu380A IUD in Tabriz, 483
- IUD (Intrauterine device)
- IUS (Intrauterine system)
- Kinshasa, Democratic Republic of Congo, prevalence and determinants of modern contraceptive use, 400
- Knowledge, on contraception, among female ED patients, 201
- between Hispanic and non-Hispanic whites, 125
- Latin America, pharmacy access to abortifacients in a city in, 394
- Leg strength, maximal, effects of androgenicity of progestin in OC pills, 487
- Leukemia inhibitory factor, monoclonal antibodies to, effects on blastocyst implantation (rhesus monkey), 419
- Levonorgestrel (LNG), vs desogestrel, skeletal effects, 367
- EC, bleeding pattern after, 118
- EC pills, bleeding patterns after use of, 349
- OC, vs contraceptive patch, cerebral venous sinus thrombosis in users of, 290
- single-dose, pharmacokinetics in adolescents vs adults, 104
- Levonorgestrel (LNG) + EE, in injectable PLG microspheres, biodegradation and biocompatibility of, 148
- safety and efficacy of continuous regimen, 439
- Levonorgestrel-releasing implant, biodegradable long-acting, preclinical studies (rats and dogs), 141
- Levonorgestrel-releasing IUS, vs OC, vs surgery, for DUB, cost-effectiveness of, 249
- LNG (Levonorgestrel) Long-acting contraceptive implant, biodegradable LNG-releasing, preclinical studies (rats and dogs), 141
- Lorazepam, or intravenous sedation, with or without local anesthesia, for pain in first-trimester surgical abortion, 407
- Manual vacuum aspiration, and buccal misoprostol, for second-trimester abortion in Vietnam, 272
- Medical abortion, contraception after, review, 56
- in early first-trimester, pharmacokinetics and regimens of misoprostol, review, 26
- in early pregnancy, in China, review, 61
- efficacy of mifepristone + misoprostol, review, 21
- efficacy of oral vs vaginal misoprostol regimens, 176
- first-trimester, vaginal vs sublingual misoprostol for cervical priming in, 328
- frequently asked questions about, review, 3
- mifepristone + prostaglandin, review, 66
- mifepristone use and risk of death, 174
- pain and analgesia requirements during, review, 45
- provider, and morality, ARHP editorial, 1
- second-trimester, manual vacuum aspiration and buccal misoprostol in Vietnam, 272
- shortened time interval of prostaglandin after mifepristone for, review, 42
- up to 10 weeks of gestation, mifepristone and multiple misoprostol doses for, review, 36
- using mifepristone, atypical presentation of PID after, 352
- women's perceptions on, review, 11
- Menstrual cycle, among users of COC vs vaginal ring, 220
- irregularity caused by hormonal contraception, adolescent women's perceptions, 214
- after LNG EC, 118
- suppression of, in extended use OC, women's and providers' attitude toward, 174
- symptoms in continuous use OC, review, 359
- after use of LNG EC pills, 349
- Metformin, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Metronidazole, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165

- Mifepristone,
atypical presentation of PID after induced abortion using, 352
in medical abortion, risk of death, 174
resulting in septic shock, due to *Clostridium sordellii*, 174
shortened time interval of prostaglandin after, for medical abortion, review, 42
- Mifepristone + misoprostol,
effects of various routes of misoprostol on uterine contractility, review, 31
efficacy in medical abortion, review, 21
multiple misoprostol doses, for abortion up to 10 weeks of gestation, review, 36
for treatment of early pregnancy failure, 458
- Mifepristone + prostaglandin,
in medical abortion, review, 66
for TOP, contraindications and rationale, review, 16
- Misoprostol,
buccal, and manual vacuum aspiration, for second-trimester abortion in Vietnam, 272
in early first-trimester medical abortion, pharmacokinetics and regimens, review, 26
for medical abortion, efficacy of oral vs vaginal regimens, 176
pharmacy access in a Latin American city, 394
shortened time interval after mifepristone for medical abortion, review, 42
sublingual vs vaginal, for cervical priming in first-trimester abortion, 328
vaginal, for TOP in women with previous single CS, 324
- Misoprostol + mifepristone,
effects of various routes of misoprostol on uterine contractility, review, 31
efficacy in medical abortion, review, 21
multiple misoprostol doses, for abortion up to 10 weeks of gestation, review, 36
for treatment of early pregnancy failure, 458
- Monoclonal antibodies, to leukemia inhibitory factor, effects on blastocyst implantation (rhesus monkey), 419
- Morality, and the abortion provider, ARHP editorial, 1
- Mortality, risk in mifepristone medical abortion, 174
- Multilingual web site, on TOP information, usage patterns of, 264
- Natural family planning, attitudes among urban Hispanic women, survey of, 313
- New Mexico, conformity of current guidelines with OC prescribing in breastfeeding women, 389
- Norgestimate, OC, vs contraceptive patch, cerebral venous sinus thrombosis in users of, 290
- Norgestimate + EE, OC vs transdermal patch, risk of nonfatal VTE in women using, 354
- NuvaRing, vs oral EE + drospirenone, efficacy, safety and tolerability, 451
- OC (Oral contraceptive)
Oral administration,
misoprostol
in early first-trimester medical abortion, pharmacokinetics of, review, 26
with mifepristone, effects on uterine contractility, review, 31
vs vaginal administration, of misoprostol
efficacy in medical abortion, 176
- Oral contraceptive (OC),
for breastfeeding women in New Mexico, conformity of prescribing practices with current guidelines, 389
combined, vs vaginal ring, cycle control, tolerability and sexual satisfaction among users, 220
continuous use, menstrual-cycle-related symptoms, review, 359
vs contraceptive patch, cerebral venous sinus thrombosis in users of, 290
- desogestrel vs LNG, skeletal effects, 367
- EE + drospirenone, vs NuvaRing, efficacy, safety and tolerability, 451
- extended-use
utilizing continuous low-dose EE, safety and efficacy, 355
women's and providers' attitude toward menstrual suppression with, 174
- vs LNG-releasing IUS, vs surgery, for DUB, cost-effectiveness of, 249
- shortened hormone-free interval causes greater inhibition of the pituitary-ovarian axis, 100
- vs transdermal patch
containing norgestimate + EE, risk of nonfatal VTE in women using, 354
effects on estrogen-sensitive hepatic proteins, 293
- Oral contraceptive (OC) pills,
effects of St. John's Wort on antiandrogenic properties of, 245
progesterin in, effects of its androgenicity on maximal leg strength, 487
- ORTHO Birth Control Satisfaction Assessment Tool, sensitivity to change and predictors of satisfaction, 303
- Ovarian function,
effects of Uniplant, 492
reduced estradiol and inhibin-B production due to shortened hormone-free interval of OC regimens, 100
- Pain,
and analgesia requirements, during medical abortion, review, 45
in first-trimester surgical abortion, effects of local anesthesia with or without lorazepam or intravenous sedation for, 407
after TOP, efficacy of suppository analgesia for, 345
- Pelvic inflammatory disease (PID), atypical presentation after mifepristone-induced medical abortion, 352

- Pharmacokinetics,
 of Centchroman, effects of coadministered drugs on (rats), 165
 of CMA and EE after single and multiple oral doses of CMA + EE, 239
 of misoprostol in early first-trimester medical abortion, review, 26
 of single-dose LNG in adolescents vs adults, 104
 of tanaproget in healthy women, 414
- Pharmacy access,
 to abortifacients in a Latin American city, 394
 direct, in France, determinants and circumstances of EC pill use in the context of, 476
 to hormonal contraception, survey on women's attitudes toward and interest in, 463
- Pioglitazone, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Pituitary gland, reduced gonadotropin secretion due to shortened hormone-free interval of OC regimens, 100
- PLG microspheres (Poly (lactide-co-glycobide) (PLG) microspheres)
 Pluronic F68/poly ϵ -caprolactone, as long-acting LNG-releasing implant, preclinical studies (rats and dogs), 141
- Poly ϵ -caprolactone/pluronic F68, as long-acting LNG-releasing implant, preclinical studies (rats and dogs), 141
- Poly (lactide-co-glycobide) (PLG) microspheres, injectable, containing LNG + EE, biodegradation and biocompatibility of, 148
- Polygonum hydropiper*, root extract, effects on follicular recruitment and endometrial hyperplasia (rats), 426
- Post-abortion care, frequently asked questions about, review, 3
- Postpartum period, early, efficacy and complications of IUD insertion, 376
- Pre-abortion care, frequently asked questions about, review, 3
- Pregnancy, early,
 experiences of medical abortion in China, review, 61
 failure of, misoprostol + mifepristone for treatment of, 458
- Premenstrual disorders, efficacy and safety of EE + drospirenone in women, 446
- Progestin, in OC pills, effects of its androgenicity on maximal leg strength, 487
- Prostaglandin, shortened time interval after mifepristone for medical abortion, review, 42
- Prostaglandin + mifepristone, in medical abortion, review, 66
 for TOP, contraindications and rationale, review, 16
- Randomized controlled trials,
 impact of advance provision vs information EC use by age and ethnicity, 110
 safety and acceptability of CS gel, 133
 skeletal effects of desogestrel vs LNG, 367
 sublingual vs vaginal misoprostol for cervical priming in first-trimester abortion, 328
- Reproductive health research, adding value to, ARHP editorial, 199
- Research, in reproductive health, adding value to, ARHP editorial, 199
- Risk, of death in mifepristone medical abortion, 174
- Root extract, of *Polygonum hydropiper*, effects on follicular recruitment and endometrial hyperplasia (rats), 426
- Safety,
 continuous LNG + EE, 439
 of CS gel, 133
 drospirenone + EE in women with premenstrual disorders, 446
 mifepristone and multiple misoprostol doses for abortion up to 10 weeks of gestation, review, 36
 NuvaRing vs oral EE + drospirenone, 451
 SeasoniqueTM, 355
 of tanaproget in healthy women, 414
- Satisfaction, ORTHO Birth Control Satisfaction Assessment Tool, 303
- SeasoniqueTM, safety and efficacy, 355
- Sedation, intravenous, or lorazepam with or without local anesthesia, for pain in first-trimester surgical abortion, 407
- Septic shock, mifepristone-induced, due to *Clostridium sordellii*, 174
- Sex-hormone-binding globulin, effects of OC vs transdermal patch, 293
- Sex workers, female, in Tashkent, Uzbekistan, relation of contraception and abortion utilization to HIV infection, 318
- Sexual behavior,
 and contraceptive use, among women, ethnic variations in, 224
 of hormonal EC users, 309
- Sexual satisfaction, among users of COC vs vaginal ring, 220
- Side effects, vaginal ring vs COC, 220
- Skeletal effects, of desogestrel vs LNG, 367
- St. John's Wort, effects on antiandrogenic properties of OC pills, 245
- Subcutaneous administration, of DMPA, bleeding patterns in, 234
- Sublingual administration,
 misoprostol in early first-trimester medical abortion, pharmacokinetics of, review, 26
 with mifepristone, effects on uterine contractility, review, 31

- Sublingual administration, (*continued*)
 vs vaginal administration, of misoprostol for cervical priming in first-trimester abortion, 328
- Suppository analgesia, efficacy in postabortion pain reduction, 345
- Surgery, vs LNG-releasing IUS, vs OC, for DUB, cost-effectiveness of, 249
- Surgical abortion, first-trimester, effects of local anesthesia with or without lorazepam or intravenous sedation for pain in, 407
- Survey,
 of attitudes on natural family planning among urban Hispanic women, 313
- conformity of current guidelines with OC prescribing in breastfeeding women in New Mexico, 389
- women's attitudes toward and interest in pharmacy access to hormonal contraception, 463
- Systematic review, Cochrane Fertility Regulation Group, best evidence on family planning, 280
- Tabriz, Iran, continuation rates and reasons for discontinuation of TCu380A IUD, 483
- Tanaproget, pharmacokinetics and safety in healthy women, 414
- Tashkent, Uzbekistan, relation of contraception and abortion utilization to HIV infection among female sex workers in, 318
- TCu380A IUD, continuation rates and reasons for discontinuation in Tabriz, Iran, 483
- Technology, contraceptive, improvement of, 350
- Teenagers, high-risk for unintended pregnancies, 471
- Termination of pregnancy (TOP),
 contraception after, review, 56
 contraindications and rationale of mifepristone + prostaglandin, review, 16
 efficacy of oral vs vaginal misoprostol regimens, 176
 efficacy of suppository analgesia for pain after, 345
 usage patterns of a multilingual web site on, 264
 in women with previous single CS, vaginal misoprostol for, 324
- Theophylline, effects on postcoital contraceptive efficacy and pharmacokinetic profile of centchroman (rats), 165
- Thrombosis, cerebral venous sinus, in users of four hormonal contraceptives, 290
- Thyroxine-binding globulin, effects of OC vs transdermal patch, 293
- Time interval, shortened, of prostaglandin after mifepristone for medical abortion, review, 42
- Tolerability,
 NuvaRing vs oral EE + drospirenone, 451
 oral vs vaginal misoprostol regimens for medical abortion, 176
- TOP (termination of pregnancy)
- Transdermal patch, vs OC, containing norgestimate + EE, risk of nonfatal VTE in women using, 354
 effects on estrogen-sensitive hepatic proteins, 293
- Unintended pregnancy, high-risk in teenagers, 471
- Uniplant, effects on endometrial morphology and ovarian function, 492
- United Kingdom, continuation rate of Implanon®, 287
- United States, timing of steps and reasons for delays in obtaining abortion, 334
- Urban population, Hispanic women, survey of attitudes on natural family planning, 313
- Uterine bleeding, dysfunctional, cost-effectiveness of surgery vs LNG-releasing IUS vs OC, 249
- Uterine contractility, after mifepristone and various routes of misoprostol, review, 31
- Uzbekistan, relation of contraception and abortion utilization to HIV infection among female sex workers in Tashkent, 318
- Vaccines, for HPV, maximizing benefit of, ARHP editorial, 277
- Vaginal administration,
 misoprostol
 in early first-trimester medical abortion, pharmacokinetics of, review, 26
 with mifepristone, effects on uterine contractility, review, 31
 for TOP in women with previous single CS, 324
 vs oral administration, of misoprostol
 efficacy in medical abortion, 176
 vs sublingual administration, of misoprostol for cervical priming in first-trimester abortion, 328
- Vaginal ring, vs COC, cycle control, side effects and sexual satisfaction among users, 220
- Venous sinus thrombosis, cerebral, in users of four hormonal contraceptives, 290
- Venous thromboembolism (VTE), nonfatal, risk in women using transdermal patch vs OC containing norgestimate + EE, 354
- Vietnam, buccal misoprostol and manual vacuum aspiration for second-trimester abortion in, 272
- VTE (Venous thromboembolism)
- Website, multilingual, on TOP information, usage patterns of, 264
- Women,
 adolescent, perceptions on menstrual irregularity caused by hormonal contraception, 214
 aged 25–35 years, effect of DMPA on BMD, 90
 attitudes toward and interest in pharmacy access to hormonal contraception 463

Women, (*continued*)

- breastfeeding, in New Mexico, conformity of OC prescribing with current guidelines, 389
- contraceptive use and knowledge among ED patients, 201
- ethnic variations in contraceptive use and sexual behavior, 224
- healthy, pharmacokinetics and safety of tanaproget, 414
- nonfatal VTE risk in users of transdermal patch vs OC containing norgestimate + EE, 354

Women, (*continued*)

- perceptions on medical abortion, review, 11
- and providers, attitudes toward menstrual suppression, with extended use of OC, 174
- sex workers in Tashkent, Uzbekistan, relation of contraception and abortion utilization to HIV infection, 318
- urban Hispanic, survey of attitudes on natural family planning, 313
- Women's health, ten priorities, ARHP editorial, 435

